KODIAK SCIENCES INC. Debt Securities, Available-for-sale, Allowance for Credit Loss
KODIAK SCIENCES INC. (KOD) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-03-31
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2023-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2022-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 |
| 2023-12-31 | $0.00 10-K · filed 2026-03-31 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-09 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 |
| 2019-12-31 | $0.00 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |